Rabemak 14s 10 mg coated tablets
- $14.50
The instruction for medical
use
of RABEMAK 10 medicine
RABEMAK 20
the Trade name
Rabemak 10
Rabemak 20
International unlicensed
name Rabeprazol Lekarstvennaya
the Tablet form, covered with a kishechnorastvorimy cover, 10 mg, 20 mg
Structure
One tablet Rabemak 10 contains
active substance - rabeprazol sodium of 10 mg,
excipients: Mannitolum, hydroxypropyl cellulose, magnesium oxide, ethyl cellulose, talc purified magnesium stearate,
structure of a cover: methacrylic acid a kopolimer of L-100, the diethyl phthalate, talc purified the titan dioxide, magnesium stearate, ferrous oxide yellow, a hydroksipropilmetiltsellyuloza, propylene glycol.
One tablet Rabemak 20 contains
active substance - rabeprazol sodium of 20 mg,
excipients: Mannitolum, hydroxypropyl cellulose, magnesium oxide, ethyl cellulose, talc purified magnesium stearate,
structure of a cover: methacrylic acid a kopolimer of L-100, the diethyl phthalate, talc purified the titan dioxide, magnesium stearate, ferrous oxide red, a hydroksipropilmetiltsellyuloza, propylene glycol.
Description
Rabemak 10: yellow color, round shape, the biconvex tablets covered with a kishechnorastvorimy cover with risky on one party and smooth on the other hand.
Rabemak 20: henna-red color, round shape, the biconvex tablets covered with a kishechnorastvorimy cover with risky on one party and smooth on the other hand.
Pharmacological group
Antiulcerous means and the drugs used at a gastroesophageal reflux. Inhibitors of the protonew pump.
The code of automatic telephone exchange A02BC04
the Pharmacological
Rabeprazol Pharmacokinetics properties is soaked up in intestines and is defined in blood plasma in 1 hour. The absolute bioavailability is 52%. Linking with proteins of blood plasma - 96.3%. It is metabolized in a liver with participation of isoenzymes of CYP2C9 and CYP3A cytochrome. The anti-secretory effect after oral administration of 20 mg occurs during 1 h and reaches a maximum in 2-4 h, oppression of basal and stimulated secretion in 23 h after reception of the first dose makes 62% (rabeprazol 10 mg) and 82% (rabeprazol 20 mg) respectively, action duration - 48 h.
Elimination half-life makes 0.7 - 1.5 hours, clearance – 283 ± 98 ml/min. It is removed by kidneys - 90% in the form of two metabolites: a conjugate of mercapturic acid and carboxylic acid, through intestines - 10%.
The pharmacodynamics
Rabemak belongs to the class of anti-secretory drugs (benzimidazole - the substituted inhibitors of the protonew pump). The mechanism of action consists in oppression of H+K+ enzyme of ATP-ase on the secretory surface of covering cells of a stomach that leads to blocking of a final stage of secretion of hydrochloric acid. Drug blocks both basal, and stimulated secretion of hydrochloric acid irrespective of the irritant nature. In covering cells of a stomach drug is protonated, collects and turns into active sulphenamide. Does not show anticholinergic action and has no properties of H2 receptors inhibitors.
Indications
- the peptic ulcer of a stomach and duodenum including associated with H.pylori
- a gastroesophageal reflux disease
- Zollingera-Ellison's syndrome.
Route of administration and doses
Peptic ulcer of a stomach and 12-perstny gut: 20 mg once a day in the morning within 4-8 weeks. For Helicobacter pylori eradikation Rabemak is used in a combination with antibacterial agents.
Gastroesophageal reflux disease: 20 mg once a day within 4-8 weeks.
Zollingera-Ellison's syndrome: 60 mg once a day.
Tablets are swallowed entirely, without chewing and without crushing.
Duration of treatment is defined individually.
Dose adjustment at elderly patients, with a renal failure or from patients with a liver failure easy and moderate severity is not required from patients.
Side effects
- a headache, dizziness, an asthenia, insomnia, hyperexcitability, drowsiness
- nausea, vomiting, an abdominal pain, a meteorism, diarrhea, a constipation, dryness in a mouth,
dyspepsia
- a fever and temperature increase, a grippopodobny syndrome, pharyngitis,
rhinitis, cough, bronchitis, sinusitis, infections of urinary tract
- nonspecific dorsodynias, myalgia, stethalgias, spasms of gastrocnemius muscles, arthralgias
- skin rashes
- increase in level of liver enzymes
of the Contraindication
- hypersensitivity to a rabeprazol, the substituted benzimidazoles or other components of drug
- pregnancy, breastfeeding.
Medicinal interactions
Rabemak does not interact with drugs which are metabolized with participation of isoenzymes of CYP450 cytochrome, such as warfarin and theophylline (at oral administration) or diazepam (at intravenous administration).
At combined use Rabemak reduces concentration in blood plasma of a ketokonazol by 30% and digoxin - for 29% therefore dose adjustment of these drugs at co-administration with Rabemak is recommended.
In view of possible interaction with antiacid drugs, Rabemak it is necessary to accept in one hour prior to or in two hours after reception of antiacid means.
Special instructions
before therapy Rabemak it is necessary to exclude existence of malignant process in a GIT which can disappear behind a mask of an ulcer.
Use in pediatrics
Is not present data on use Rabemak in the nursery
the practician Osobennosti influence of medicine on ability to run transport or potentially dangerous mechanisms
Considering side effects of drug it is necessary to be careful at control of transport or potentially dangerous mechanisms
Overdose
Symptoms: strengthening of side effects is possible.
Treatment: gastric lavage and symptomatic therapy.
There is no specific antidote. Rabeprazol does not leave at dialysis.
Form of release and packing
Rabemak of the 10th No. 30, Rabemak of the 20th No. 30
Primary packing: a strip from aluminum foil on 10 tablets.
Secondary packing: 3 strips in a cardboard pack together with the instruction for use.
Rabemak of the 10th No. 14, Rabemak of the 20th No. 14
Primary packing: a strip from aluminum foil on 7 tablets.
Secondary packing: 2 strips in a cardboard pack together with the instruction for use.
To Store storage conditions in dry, protected from light, the place at a temperature not over 250C.
To store out of children's reach!
2 years
not to apply a period of storage after an expiration date.
Prescription status
According to the prescription
Macleods Pharmaceuticals Limited Producer
304, Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai – 400,059, India.
use
of RABEMAK 10 medicine
RABEMAK 20
the Trade name
Rabemak 10
Rabemak 20
International unlicensed
name Rabeprazol Lekarstvennaya
the Tablet form, covered with a kishechnorastvorimy cover, 10 mg, 20 mg
Structure
One tablet Rabemak 10 contains
active substance - rabeprazol sodium of 10 mg,
excipients: Mannitolum, hydroxypropyl cellulose, magnesium oxide, ethyl cellulose, talc purified magnesium stearate,
structure of a cover: methacrylic acid a kopolimer of L-100, the diethyl phthalate, talc purified the titan dioxide, magnesium stearate, ferrous oxide yellow, a hydroksipropilmetiltsellyuloza, propylene glycol.
One tablet Rabemak 20 contains
active substance - rabeprazol sodium of 20 mg,
excipients: Mannitolum, hydroxypropyl cellulose, magnesium oxide, ethyl cellulose, talc purified magnesium stearate,
structure of a cover: methacrylic acid a kopolimer of L-100, the diethyl phthalate, talc purified the titan dioxide, magnesium stearate, ferrous oxide red, a hydroksipropilmetiltsellyuloza, propylene glycol.
Description
Rabemak 10: yellow color, round shape, the biconvex tablets covered with a kishechnorastvorimy cover with risky on one party and smooth on the other hand.
Rabemak 20: henna-red color, round shape, the biconvex tablets covered with a kishechnorastvorimy cover with risky on one party and smooth on the other hand.
Pharmacological group
Antiulcerous means and the drugs used at a gastroesophageal reflux. Inhibitors of the protonew pump.
The code of automatic telephone exchange A02BC04
the Pharmacological
Rabeprazol Pharmacokinetics properties is soaked up in intestines and is defined in blood plasma in 1 hour. The absolute bioavailability is 52%. Linking with proteins of blood plasma - 96.3%. It is metabolized in a liver with participation of isoenzymes of CYP2C9 and CYP3A cytochrome. The anti-secretory effect after oral administration of 20 mg occurs during 1 h and reaches a maximum in 2-4 h, oppression of basal and stimulated secretion in 23 h after reception of the first dose makes 62% (rabeprazol 10 mg) and 82% (rabeprazol 20 mg) respectively, action duration - 48 h.
Elimination half-life makes 0.7 - 1.5 hours, clearance – 283 ± 98 ml/min. It is removed by kidneys - 90% in the form of two metabolites: a conjugate of mercapturic acid and carboxylic acid, through intestines - 10%.
The pharmacodynamics
Rabemak belongs to the class of anti-secretory drugs (benzimidazole - the substituted inhibitors of the protonew pump). The mechanism of action consists in oppression of H+K+ enzyme of ATP-ase on the secretory surface of covering cells of a stomach that leads to blocking of a final stage of secretion of hydrochloric acid. Drug blocks both basal, and stimulated secretion of hydrochloric acid irrespective of the irritant nature. In covering cells of a stomach drug is protonated, collects and turns into active sulphenamide. Does not show anticholinergic action and has no properties of H2 receptors inhibitors.
Indications
- the peptic ulcer of a stomach and duodenum including associated with H.pylori
- a gastroesophageal reflux disease
- Zollingera-Ellison's syndrome.
Route of administration and doses
Peptic ulcer of a stomach and 12-perstny gut: 20 mg once a day in the morning within 4-8 weeks. For Helicobacter pylori eradikation Rabemak is used in a combination with antibacterial agents.
Gastroesophageal reflux disease: 20 mg once a day within 4-8 weeks.
Zollingera-Ellison's syndrome: 60 mg once a day.
Tablets are swallowed entirely, without chewing and without crushing.
Duration of treatment is defined individually.
Dose adjustment at elderly patients, with a renal failure or from patients with a liver failure easy and moderate severity is not required from patients.
Side effects
- a headache, dizziness, an asthenia, insomnia, hyperexcitability, drowsiness
- nausea, vomiting, an abdominal pain, a meteorism, diarrhea, a constipation, dryness in a mouth,
dyspepsia
- a fever and temperature increase, a grippopodobny syndrome, pharyngitis,
rhinitis, cough, bronchitis, sinusitis, infections of urinary tract
- nonspecific dorsodynias, myalgia, stethalgias, spasms of gastrocnemius muscles, arthralgias
- skin rashes
- increase in level of liver enzymes
of the Contraindication
- hypersensitivity to a rabeprazol, the substituted benzimidazoles or other components of drug
- pregnancy, breastfeeding.
Medicinal interactions
Rabemak does not interact with drugs which are metabolized with participation of isoenzymes of CYP450 cytochrome, such as warfarin and theophylline (at oral administration) or diazepam (at intravenous administration).
At combined use Rabemak reduces concentration in blood plasma of a ketokonazol by 30% and digoxin - for 29% therefore dose adjustment of these drugs at co-administration with Rabemak is recommended.
In view of possible interaction with antiacid drugs, Rabemak it is necessary to accept in one hour prior to or in two hours after reception of antiacid means.
Special instructions
before therapy Rabemak it is necessary to exclude existence of malignant process in a GIT which can disappear behind a mask of an ulcer.
Use in pediatrics
Is not present data on use Rabemak in the nursery
the practician Osobennosti influence of medicine on ability to run transport or potentially dangerous mechanisms
Considering side effects of drug it is necessary to be careful at control of transport or potentially dangerous mechanisms
Overdose
Symptoms: strengthening of side effects is possible.
Treatment: gastric lavage and symptomatic therapy.
There is no specific antidote. Rabeprazol does not leave at dialysis.
Form of release and packing
Rabemak of the 10th No. 30, Rabemak of the 20th No. 30
Primary packing: a strip from aluminum foil on 10 tablets.
Secondary packing: 3 strips in a cardboard pack together with the instruction for use.
Rabemak of the 10th No. 14, Rabemak of the 20th No. 14
Primary packing: a strip from aluminum foil on 7 tablets.
Secondary packing: 2 strips in a cardboard pack together with the instruction for use.
To Store storage conditions in dry, protected from light, the place at a temperature not over 250C.
To store out of children's reach!
2 years
not to apply a period of storage after an expiration date.
Prescription status
According to the prescription
Macleods Pharmaceuticals Limited Producer
304, Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai – 400,059, India.
Related Products
Probiotical S.p.A. (Italy)
Jogurt Babydrops for infants and children of 10 ml drops in the vial with a pipette
$24.10
